Photoreceptor phosphodiesterase 6 (PDE6)

Photoreceptor phosphodiesterase 6 (PDE6) is a retina-specific enzyme essential for visual transduction in vertebrate rod and cone photoreceptor cells[1][2][7]. It is a peripheral membrane protein composed of two catalytic subunits (alpha and beta in rods or alpha’ in cones) and two inhibitory gamma subunits forming a tetramer[1][2]. PDE6 hydrolyzes cyclic GMP (cGMP), which is the key second messenger regulating the opening of cGMP-gated cation channels in response to light. Activation of PDE6 by transducin (the visual G protein) upon photon absorption leads to rapid cGMP hydrolysis, closure of ion channels, and hyperpolarization of the photoreceptor cell—a central event in the conversion of light to neural signal (phototransduction)[1][2][5][7]. Mutations in any of the PDE6 subunit genes disrupt this process, causing hereditary retinal diseases. While not a primary drug target, PDE6 interacts with various pharmacological inhibitors, especially those developed for PDE5, causing off-target visual side effects[3][6][7]. Its complex regulation involves allosteric interactions among subunits and domains, and its centrality in vision makes it a well-characterized model for G protein-regulated enzymes[1][2][5][7].

Other names

Phosphodiesterase type 6cGMP-phosphodiesteraserod/cone PDE6PDE6A (alpha subunit)PDE6B (beta subunit)PDE6C (cone alpha’ subunit)PDE6G (gamma inhibitory subunit)PDE6H (cone gamma subunit)

Inhibition of PDE6 increases cGMP levels in photoreceptors, affecting the phototransduction cascade[3]. Drugs compete with the inhibitory γ subunit and substrate for the enzyme's active site[3]. Off-target inhibition of PDE6 by PDE5 inhibitors is responsible for some visual side effects (blue-tinged vision) seen with these medications[3].